The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Fidelity Select Pharmaceuticals Port FPHAX
- NAV / 1-Day Return 27.36 / +0.70 %
- Total Assets 1.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.700%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield 0.50%
- Turnover 44%
USD | NAV as of May 01, 2024 | 1-Day Return as of May 01, 2024, 10:14 PM GMT+0
Morningstar’s Analysis FPHAX
Will FPHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 70.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 23.34 | 308.5 Mil | Healthcare |
Novo Nordisk A/S ADR | 15.42 | 203.9 Mil | Healthcare |
AstraZeneca PLC ADR | 8.24 | 108.9 Mil | Healthcare |
Merck & Co Inc | 4.87 | 64.4 Mil | Healthcare |
GSK PLC ADR | 4.61 | 61.0 Mil | Healthcare |
UCB SA | 3.83 | 50.7 Mil | Healthcare |
Fidelity Cash Central Fund | 3.02 | 40.0 Mil | Cash and Equivalents |
Gilead Sciences Inc | 2.87 | 37.9 Mil | Healthcare |
Moderna Inc | 2.82 | 37.3 Mil | Healthcare |
Royalty Pharma PLC Class A | 2.74 | 36.2 Mil | Healthcare |